Unmasking a fungal fire

Area of Science:

• Immunology
• Oncology
• Infectious Diseases

Background:

• Immune checkpoint inhibitor (ICI) therapy is a significant advancement in cancer treatment.
• ICIs work by reactivating T cells to combat cancer cells within the tumor microenvironment.
• Emerging evidence suggests ICI therapy may influence chronic infections, especially fungal pathogens.

Purpose of the Study:

• To review recent findings on the role of immune checkpoint blockade in fungal infection outcomes.
• To summarize observations linking ICI therapy to altered susceptibility or resolution of chronic fungal infections.

Main Methods:

• Literature review of recent observations and findings.
• Synthesis of data implicating immune checkpoint blockade in fungal infection contexts.

Main Results:

• ICI therapy's impact on anticancer immunity is well-established.
• ICI therapy is increasingly associated with changes in chronic infection dynamics.
• Specific effects on fungal infections, including susceptibility and resolution, are under investigation.

Conclusions:

• Immune checkpoint blockade has implications beyond cancer treatment.
• Further research is needed to fully understand the relationship between ICI therapy and fungal infections.
• Understanding these interactions is crucial for managing patients undergoing ICI therapy.